ASH 2017 | New nivolumab combination therapies for AML
There has historically been less novel agents being tested and moving into the clinic for AML. Now, there has been a wave of promising trials. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Naval Daver, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of the ongoing Phase II study (NCT02397720) of nivolumab plus azacitidine in patients with relapsed AML or frontline elderly AML. Dr Daver emphasizes the impact of the good response rates seen, even in elderly salvage patients. Additionally, Dr Daver provides an overview of two other promising studies, one looking at nivolumab/idarubicin combination therapy and another investigating T-cell populations in AML, providing insights into the best immune checkpoints to target therapeutically.
Get great new content delivered to your inboxSign up